Showing results (31-40 of 36) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
The Journal of Antimicrobial Chemotherapy|July 16, 2015
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)S Bonora, S Rusconi, A Calcagno, et al.Antimicrobial Agents and Chemotherapy|August 30, 2005
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical settingD González de Requena, S Bonora, S Garazzino, et al.Current HIV Research|August 10, 2014
Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patientsS Bonora, A Calcagno, O Vigano, et al.Antimicrobial Agents and Chemotherapy|February 6, 2013
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal functionA Calcagno, D Gonzalez de Requena, M Simiele, et al.The Journal of Antimicrobial Chemotherapy|February 2, 2008
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferonD Aguilar Marucco, D Gonzalez de Requena, S Bonora, et al.The Journal of Antimicrobial Chemotherapy|December 19, 2018
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIVA Borghetti, A Calcagno, F Lombardi, et al.Pageof 4